Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM G WIERDA and LORETTA NASTOUPIL.
Connection Strength
0.212
-
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb; 6(2):e100-e109.
Score: 0.168
-
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 11 21; 134(21):1811-1820.
Score: 0.044